Obesity Canada - Obésité Canada

Could your statin cholesterol medication cause diabetes? If you have diabetes, how much might your sugars rise with statin therapy? Read more from Dr. Sue; https://buff.ly/4fKE07q

Today’s the deadline -There have been significant advancements in research, treatment options, education, and awareness related to obesity. Obesity Canada is at the forefront of many of these changes and seeks dedicated professionals to join its Board of Directors. Apply by July 31. For more details, visit https://buff.ly/3xA0iYb or contact Nicole Pearce at [email protected]. Together, we can drive positive change in obesity management.

Have you ever been treated badly because of your weight? We would like to hear from you! You are invited to tell us in a survey about one or more experiences you have had with weight-based prejudice. This research is being led by Dr. Sarah Nutter at the University of Victoria. You are eligible to take part if you are 18 or over and live in Canada, link to the survey can be found here; https://buff.ly/3XxDEuk

Canada is the first country in the world to have once weekly insulin available, as a treatment of diabetes. Learn more about it here, Dr. Sue; https://buff.ly/3W5Qu0l

There have been significant advancements in research, treatment options, education, and awareness related to obesity. Obesity Canada is at the forefront of many of these changes and seeks dedicated professionals to join its Board of Directors. Apply by July 31. For more details, visit https://buff.ly/4ceXQW8 or contact Nicole Pearce at [email protected]. Together, we can drive positive change in obesity management.

We are delighted to announce the arrival of our new Executive Director, Lisa Schaffer! The
business acumen Lisa has developed over the years and the strong connections she has made with the obesity community, particularly with people with lived experience, clinicians and researchers, are the skills Obesity Canada needs to impact the lives of Canadians. Please join us in welcoming Lisa to the team! Stay tuned for more updates and exciting developments. https://buff.ly/3XWgE8u

Can semaglutide (Ozempic/Wegovy) cause loss of vision? Read more from Dr. Sue; https://buff.ly/3Y0glJT

Take the NextStep – Did you know over 6% of Canadian adults have prediabetes, putting them at high risk of developing type 2 diabetes? You may be one of these individuals. Find out if you are at risk of type 2 diabetes and join the Next Steps Survey to share your thoughts about type 2 diabetes prevention care in Canada https://buff.ly/3xNP9mJ

There have been significant advancements in research, treatment options, education, and awareness related to obesity. Obesity Canada is at the forefront of many of these changes and seeks dedicated professionals to join its Board of Directors. Apply by July 31. For more details, visit https://buff.ly/3KZL2He or contact Nicole Pearce at [email protected]. Together, we can drive positive change in obesity management.

Can tirzepatide (Mounjaro/Zepbound) treat obstructive sleep apnea... and maybe even eliminate the need for a CPAP machine for some people? Read about the SURMOUNT OSA results here! from Dr. Sue; https://buff.ly/4ePr9jE

What should we do with GLP1 medications for obesity or diabetes before surgery or sedation? Dr Sue was invited to be a panelist at the American Diabetes Association meeting, with anesthesiology and gastroenterology experts at the table. Find out what they said! https://buff.ly/3xvEsVK

Have you ever been treated badly because of your weight? We would like to hear from you! You are invited to tell us in a survey about one or more experiences you have had with weight-based prejudice. This research is being led by Dr. Sarah Nutter at the University of Victoria. You are eligible to take part if you are 18 or over and live in Canada, link to the survey can be found here; https://buff.ly/45B1W8K

Join My Weight - What To Know and Psychiatrist Dr. Sanjeev Sockalingam to talk about how mental health impacts weight management, the psychological challenges faced by people living with obesity and effective strategies for improving physical and mental well-being. Dr. Sockalingam is the Scientific Director of Obesity Canada, so we’ll also cover how Canadians can get involved in advocating for people with obesity! on Facebook Live, on Wednesday, June 19 at 8pm EDT; https://buff.ly/3VOFWE6

Join us tomorrow evening at 8 pm ET for an interview with Obesity Canada - Obésité Canada's scientific director Dr. Sanjeev Sockalingam, about obesity and mental health, the importance of advocacy and the exciting advances happening in the obesity space. You won't want to miss it!

Preventing or rebuilding muscle loss from weight management medication - is dietary protein or physical activity more important? Read more from Dr. Sue; https://buff.ly/4cm9gqO

There have been significant advancements in research, treatment options, education, and awareness related to obesity. Obesity Canada is at the forefront of many of these changes and seeks dedicated professionals to join its Board of Directors. If you have strong communication skills and experience in governance or relevant fields, we want to hear from you! Apply by July 31. For more details, visit https://buff.ly/3VE8C2g or contact Nicole Pearce at [email protected]. Together, we can drive positive change in obesity management.

Join Us for the Run for Her Life 2024 in Support of Gynecologic Cancer Awareness. We are thrilled to announce that Obesity Canada has partnered with The Society of Gynecologic Oncology of Canada (GOC) for an exhilarating event during the GOC’s 45th Annual General Meeting. For more information or to donate; https://buff.ly/3Vv1m8N

Why is it so important to watch blood pressure on weight management medications, especially the highly effective medications? Read more from Dr.Sue; https://buff.ly/4580hqM

The International Consortium for Health Outcomes Measurement (ICHOM) is a non-profit organization. We work with healthcare professionals, researchers, and patient representatives worldwide to define the outcomes that matter most to patients. ICHOM encourages healthcare organizations to measure these outcomes to help improve their services, which in turn provide better results for the patients.

The ICHOM Obesity Working Group has reached an agreement on the Set of Patient-Centered Outcome Measures (the Set) - consisting of outcomes most important to people with Obesity, as well as outcome measures, case-mix variables and time points to measure these outcomes in clinical practice.

We would like to seek feedback from Obesity professionals and experts on the relevance of these elements to ensure the practicability of the Set. Please use the link to the fill out the survey.

Online Survey Software | Qualtrics Survey Solutions Qualtrics sophisticated online survey software solutions make creating online surveys easy. Learn more about Research Suite and get a free account today.

Research Participation Opportunity: If you meet the eligibility criteria and are interested in participating, follow the qr code or link https://buff.ly/3wRnPDL !

Hot off the presses! Semaglutide protects kidneys and saves lives in people with type 2 diabetes and chronic kidney disease. Read more by Dr. Sue https://buff.ly/4e869EK

We know that GLP-1 receptor agonist medications reduce heart attack and stroke risk in people with diabetes, and in people with obesity. But what happens to risk of cardiovascular events if GLP-1 receptor agonist treatment is stopped? Read more for Dr. Sue; https://buff.ly/3QQrhVI

RESEARCH PARTICIPATION OPPORTUNITY:

The ‘Obesity Care in Canada Priority Setting Partnership (PSP)’ has launched a survey
to begin developing research priorities for obesity care in Canada.

Are you an adult (18 years of age or older) living with obesity who has accessed obesity
care in Canada? Or are you a caregiver or health care provider that supports adults
living with obesity and accessing obesity care in Canada? If so, we want to know what
questions you have about adult obesity care in Canada. Tell us what matters to you!
With your help, we can ensure researchers are investigating what matters most to those
receiving obesity care and those who support individuals living with obesity

Click the link to get started!

https://buff.ly/3ycGxWK

Wegovy (semaglutide 2.4mg for weight management) is now available at Canadian pharmacies. What do you need to know? Read more from Dr. Sue; https://buff.ly/3QzEvpV

Obesity Canada's Director of Advocacy and Public Engagement, Ian Patton, was interviewed for this piece about the upcoming launch of Wegovy in Canada, along with Dr. Macklin and Dr. Sajwani. Having effective, evidence-based treatment options available to Canadians living with obesity is important and we are happy that there are more options now. We also need to recognize that for many Canadians, having a treatment available, does not mean it will be accessible. Along with these advancements in treatment and management of obesity, we need policy and coverage for all the pillars of obesity management from the Clinical Practice Guidelines to evolve as well to treat obesity like any other chronic disease.

CTV National News: Wegovy comes to Canada Ozempic's sister drug Wegovy is now available in Canada but many might still be wondering what's the difference? Allison Bamford explains.

RESEARCH PARTICIPATION OPPORTUNITY:

The ‘Obesity Care in Canada Priority Setting Partnership (PSP)’ has launched a survey
to begin developing research priorities for obesity care in Canada.

Are you an adult (18 years of age or older) living with obesity who has accessed obesity
care in Canada? Or are you a caregiver or health care provider that supports adults
living with obesity and accessing obesity care in Canada? If so, we want to know what
questions you have about adult obesity care in Canada. Tell us what matters to you!
With your help, we can ensure researchers are investigating what matters most to those
receiving obesity care and those who support individuals living with obesity

Click the link to get started!

https://buff.ly/4bbrvih

As many as 1 BILLION adults worldwide are estimated to have obstructive sleep apnea (OSA), and 70% of people with OSA have obesity. How much does sleep apnea improve with weight loss, and does it matter how the weight is lost (with lifestyle, weight management medication, or bariatric surgery)? Learn more from Dr. Sue; https://buff.ly/446i8y1

Semaglutide 2.4mg has now shown benefit to treat heart failure (HFpEF) in people with or without type 2 diabetes. What important points can we learn from the new data? Learn more from Dr. Sue; https://buff.ly/3JiwjpY

Older data have shown that only about 2% of people with obesity received treatment with medication. With the changes in the weight management world in recent years, has this impacted prescribing of medication? Listen or read more with Dr. Sue; https://buff.ly/3Jdtt5A